2017-10-11 19:20:44 UTC

Duration of Hepatitis C Virus Therapy

Oct. 11, 2017

Shorter duration therapy reduces treatment costs and may also improve adherence. How short can therapy be and who would qualify?

Guidelines for the treatment of chronic hepatitis C virus (HCV) do not encourage treatment for less than 12 weeks. Benjamin Emmanuel, MPH, Eleanor M. Wilson, MD, and Shyam Kottilil, MD, PhD, explain in AGA Perspectives that there is mounting evidence that many patients can achieve sustained virologic response with only eight weeks of treatment. The shorter duration therapy substantially reduces treatment costs and may also improve adherence as adherence tends to decrease as therapy duration increases. 

The authors recommend further exploration into shorter HCV therapy in target populations to address some of the issues that may arise, such as optimal retreatment strategies and the emergence of resistance-associated variants. 

Read the full article in AGA Perspectives.

More on Hepatitis C

2018 AGA Postgraduate Course Resources

Jan. 17, 2018

Pre-order resources from the course when you register.

Save the Date: 2018 AGA Postgraduate Course

Jan. 11, 2018

This year’s course will take place on June 2 and 3, 2018, in Washington, D.C.

Compendium of AGA 2017 Clinical Guidance

Dec. 21, 2017

Are you up-to-date on AGA's latest clinical guidance?